Senseonics Holdings, Inc. (NYSE American: SENS) saw its stock price plummet 5.66% in pre-market trading on Tuesday, following the company's announcement of its preliminary third-quarter revenue and plans for a reverse stock split. The medical technology company, which specializes in implantable continuous glucose monitoring systems, faces a negative market reaction despite reporting growth in revenue and patient numbers.

According to the company's preliminary unaudited results, Senseonics generated revenue of approximately $8.1 million in the third quarter of 2025, representing a 91% increase compared to the same period last year. This growth was primarily driven by a 160% increase in new patient starts in the U.S. market. Despite exceeding analysts' expectations of $7.8 million in revenue, investors appear to be focusing on other aspects of the announcement.

The market's negative response seems to be largely influenced by Senseonics' decision to implement a 1-for-20 reverse stock split, set to take effect on October 17, 2025. This move will reduce the number of outstanding common shares from about 816 million to approximately 41 million. While reverse stock splits are often implemented to maintain compliance with stock exchange listing requirements or to potentially attract institutional investors, they can sometimes be perceived negatively by the market. The combination of these announcements, despite the company's growth in revenue and patient numbers, appears to have triggered a sell-off in the pre-market session, reflecting investor uncertainty about Senseonics' future prospects and financial stability.